Part of SEATTLE CHILDREN'S HOSPITAL
Clinical Trials
212
29 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
17
8.0%
Completed
121
57.1%
Enrolling By Invitation
2
0.9%
Not yet recruiting
10
4.7%
Recruiting
32
15.1%
Suspended
1
0.5%
Terminated
8
3.8%
Unknown
17
8.0%
Withdrawn
4
1.9%
- A multi-center prospective cohort study (CHICKADEE) will enroll 300 children aged 4–16 years, 4–12 years after their first cardiac surgery requiring cardiopulmonary bypass, to characterize the natural history of hypertension and kidney disease in congenital heart disease. - The study integrates 24-hour ambulatory blood pressure monitoring, novel glomerular and tubular biomarkers, proteomics, and genetic characterization to detect subclinical kidney injury and identify risk factors beyond traditional measures. - Prior data show hypertension (12%–17%), albuminuria (8%), and chronic kidney disease (21%–30%) emerge in childhood after cardiac surgery, yet only 4% of affected children are evaluated by a pediatric nephrologist. - Recruitment began March 1, 2025, with data collection expected to conclude by December 2027 and results anticipated by June 2028.
- Blank Bio closed a $7.2 million seed financing round and formed a strategic collaboration with Pacific Biosciences to develop RNA foundation models for precision oncology applications. - The partnership will generate PacBio HiFi long-read RNA sequencing data from up to 100 patient tumor samples to train AI models that capture molecular complexity beyond standard gene-level summaries. - The company's RNA foundation models aim to improve patient stratification, biomarker discovery, and clinical trial design by extracting patient-level variation from bulk RNA-seq data that traditional pipelines discard. - Blank Bio will deploy its technology across predictive biomarkers, prognostic modeling, and clinical diagnostics to support pharmaceutical and diagnostic companies in oncology applications.
- A phase 2 clinical trial demonstrated that 27 of 28 patients (96%) with leukemias and myelodysplastic syndrome survived at least one year after receiving a novel cord blood transplant approach. - The innovative treatment combines traditional cord blood transplantation with dilanubicel, a pooled stem cell product derived from six to eight different cord blood units. - None of the patients experienced severe acute or chronic graft-versus-host disease, addressing a major complication of stem cell transplantation. - The pooled stem cells provided essential early immune support without long-term engraftment, helping establish a healthy immune system in patients.
- A multi-site study of over 600 cystic fibrosis patients found that those on elexacaftor/tezacaftor/ivacaftor (ETI) triple-drug therapy can safely reduce many daily lung treatments while maintaining good health for years. - Teens and adults cut their use of chronic respiratory therapies by nearly half, with younger children showing similar trends, without experiencing loss of lung function or increased respiratory symptoms. - The findings suggest a significant reduction in treatment burden for CF patients, potentially improving quality of life while maintaining clinical outcomes through personalized care decisions.
- St. Jude researchers analyzed data from nearly 900 pediatric medulloblastoma patients across three clinical trials to develop new treatment risk groups that could safely reduce therapy intensity. - The study found that 40% of medulloblastoma patients can receive lower doses of craniospinal radiation therapy and almost all can receive less chemotherapy while maintaining equivalent survival outcomes. - Scientists created the Medulloblastoma Meta-Analysis Portal, a web-based tool that allows physicians to predict patient outcomes using demographic, clinical and molecular features through a point-and-click interface. - The research identified four actionable treatment recommendation groups based on molecular features including chromosome alterations, methylation subgroups and MYC oncogene amplifications in G3 and G4 tumor types.
- The Washington Research Foundation has awarded $5.2 million to establish a collaborative clinical trials program between Fred Hutch Cancer Center and Seattle Children's Research Institute focusing on first-in-human studies of novel therapeutics for rare cancers. - The program will prioritize two engineered T-cell therapies: a TCR T-cell therapy for high-risk acute myeloid leukemia in adults and a CAR T-cell therapy for AML in children, selected from over a dozen evaluated technologies. - Four million dollars will directly support four Phase 1 clinical trials (two at each institution), while $1.2 million will fund strategic planning and infrastructure development to create a sustainable framework for translating innovative therapies.
- The Children's Oncology Group AALL1731 trial received the David Sackett Trial of the Year Award for demonstrating that adding blinatumomab to chemotherapy reduces relapse risk by about two-thirds in children with B-cell acute lymphoblastic leukemia. - Children receiving the combination therapy achieved a 96% three-year disease-free survival rate compared to 87.9% with chemotherapy alone, representing a 61% reduction in risk of relapse, secondary malignancy, or remission-related death. - The study findings have established a new standard of care for pediatric B-ALL worldwide and represent the biggest breakthrough in childhood cancer treatment in decades. - The trial enrolled 4,264 newly diagnosed patients and ended early in July 2024 after interim analysis showed better outcomes than expected with the combination therapy.
- A phase I clinical trial demonstrates the feasibility and tolerability of repeated intraventricular B7-H3 CAR T-cell infusions in children with DIPG. - One patient with DIPG showed sustained clinical and radiographic improvement for 12 months following B7-H3 CAR T-cell therapy. - The study provides correlative evidence of local immune activation and persistent CAR T cells in the cerebrospinal fluid of treated patients. - Targeted mass spectrometry reveals modulation of key immune analytes in the CSF, suggesting potential biomarkers for therapy response.
